These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 26058730

  • 21. Clinical assessment of Optivate®, a high-purity concentrate of factor VIII with von Willebrand factor, in the management of patients with haemophilia A.
    Dmoszynska A, Kuliczkowski K, Hellmann A, Trelinski J, Kloczko J, Baglin T, Hay C, O'Shaughnessy D, Zawilska K, Makris M, Shaikh-Zaidi R, Gascoigne E, Dash C.
    Haemophilia; 2011 May; 17(3):456-62. PubMed ID: 21371184
    [Abstract] [Full Text] [Related]

  • 22. A postmarketing surveillance study of the safety and efficacy of ReFacto (St Louis-derived active substance) in patients with haemophilia A.
    Smith MP, Giangrande P, Pollman H, Littlewood R, Kollmer C, Feingold J, Refacto St Louis Study Group.
    Haemophilia; 2005 Sep; 11(5):444-51. PubMed ID: 16128886
    [Abstract] [Full Text] [Related]

  • 23. Efmoroctocog Alfa: A Review in Haemophilia A.
    Frampton JE.
    Drugs; 2016 Sep; 76(13):1281-1291. PubMed ID: 27487799
    [Abstract] [Full Text] [Related]

  • 24. Beriate® P in the treatment of patients with haemophilia A: results of a long-term pharmacovigilance study.
    Klamroth R, Holzhauer S, Zimmermann R, Heller C, Kurnik K, Beriate® Pharmacovigilance Group.
    Thromb Res; 2014 Nov; 134 Suppl 1():S16-21. PubMed ID: 24418255
    [Abstract] [Full Text] [Related]

  • 25. Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A.
    Auerswald G, Thompson AA, Recht M, Brown D, Liesner R, Guzmán-Becerra N, Dyck-Jones J, Ewenstein B, Abbuehl B.
    Thromb Haemost; 2012 Jun; 107(6):1072-82. PubMed ID: 22476554
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results.
    Lalezari S, Reding MT, Pabinger I, Holme PA, Negrier C, Chalasani P, Shin HJ, Wang M, Tseneklidou-Stoeter D, Maas Enriquez M.
    Haemophilia; 2019 Nov; 25(6):1011-1019. PubMed ID: 31621991
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan.
    Taki M, Fukutake K, Matsushita T, Nogami K, Shima M, Yoshioka A, Takamatsu J, Arai M, Takagi H, Uchikawa H, Engl W, Shirahata A.
    Int J Hematol; 2019 Jan; 109(1):70-78. PubMed ID: 30043332
    [Abstract] [Full Text] [Related]

  • 34. Efficacy and safety of low-dose prophylaxis of highly purified plasma-derived factor VIII concentrate produced by the National Blood Centre, Thai Red Cross Society.
    Chuansumrit A, Sosothikul D, Natesirinilkul R, Lektrakul Y, Charoonruangrit U, Factor VIII Study Group.
    Haemophilia; 2018 Sep; 24(5):e387-e390. PubMed ID: 30117632
    [No Abstract] [Full Text] [Related]

  • 35. A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A.
    Richards M, Williams M, Chalmers E, Liesner R, Collins P, Vidler V, Hanley J, Paediatric Working Party of the United Kingdom Haemophilia Doctors' Organisation.
    Br J Haematol; 2010 May; 149(4):498-507. PubMed ID: 20230411
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.